Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus

References

• Manzi S., Selzer F., Sutton‐Tyrrell K., Fitzgerald S. G., Rairie J. E., Tracy R. P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51–60
   PubMed Web of Science ®Google Scholar
• Bjornadal L., Yin L., Granath F., Klareskog L., Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population‐based study 1964–95. J Rheumatol 2004; 31: 713–19
   PubMed Web of Science ®Google Scholar
• Esdaile J. M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–7
   PubMed Web of Science ®Google Scholar
• Cederholm A., Svenungsson E., Stengel D., Fei G. Z., Pockley A. G., Ninio E., et al. Platelet‐activating factor‐acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2869–76
   PubMedGoogle Scholar
• Doria A., Shoenfeld Y., Wu R., Gambari P. F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071–7
   PubMed Web of Science ®Google Scholar
• Frostegard J., Svenungsson E., Wu R., Gunnarsson I., Lundberg I. E., Klareskog L., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192–200
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Fei G. Z., Jensen‐Urstad K., de Faire U., Hamsten A., Frostegard J. TNF‐alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 454–61
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Jensen‐Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–93
   PubMed Web of Science ®Google Scholar
• Asanuma Y., Oeser A., Shintani A. K., Turner E., Olsen N., Fazio S., et al. Premature coronary‐artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–15
   PubMed Web of Science ®Google Scholar
• Roman M. J., Shanker B. A., Davis A., Lockshin M. D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406
   PubMed Web of Science ®Google Scholar
• Drenkard C., Villa A. R., Alarcón‐Segovia D., Pérez‐Vázquez M. E. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 1067–72
   PubMed Web of Science ®Google Scholar
• Cederholm A., Svenungsson E., Jensen‐Urstad K., Trollmo C., Ulfgren A. K., Swedenborg J., et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198–203
   PubMed Web of Science ®Google Scholar
• Sallai K. K., Nagy E., Bodo I., Mohl A., Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36: 198–205
   PubMed Web of Science ®Google Scholar
• Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257: 485–95
   PubMed Web of Science ®Google Scholar
• Celermajer D. S., Sorensen K. E., Gooch V. M., Spiegelhalter D. J., Miller O. I., Sullivan I. D., et al. Non‐invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–15
   PubMed Web of Science ®Google Scholar
• Anderson T. J., Gerhard M. D., Meredith I. T., Charbonneau F., Delagrange D., Creager M. A., et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71–4B
   PubMed Web of Science ®Google Scholar
• Yeboah J., Crouse J. R., Hsu F. C., Burke G. L., Herrington D. M. Brachial flow‐mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115: 2390–7
   PubMed Web of Science ®Google Scholar
• Chan S. Y., Mancini G. B., Kuramoto L., Schulzer M., Frohlich J., Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003; 42: 1037–43
   PubMed Web of Science ®Google Scholar
• Conway E. M., Van de Wouwer M., Pollefeyt S., Jurk K., Van Aken H., De Vriese A., et al. The lectin‐like domain of thrombomodulin confers protection from neutrophil‐mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen‐activated protein kinase pathways. J Exp Med 2002; 196: 565–77
   PubMed Web of Science ®Google Scholar
• Hansson G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95
   PubMed Web of Science ®Google Scholar
• Price D. T., Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85–97
   PubMed Web of Science ®Google Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Liang M. H., Socher S. A., Roberts W. N., Esdaile J. M. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988; 31: 817–25
   PubMed Web of Science ®Google Scholar
• Gladman D., Ginzler E., Goldsmith C., Fourtin P., Liang M., Urowitz M., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–9
   PubMed Web of Science ®Google Scholar
• Wikstrand J., Wendelhag I. Methodological considerations of ultrasound investigation of intima–media thickness and lumen diameter. J Intern Med 1994; 236: 555–9
   PubMed Web of Science ®Google Scholar
• Jensen‐Urstad K., Rosfors S. A methodological study of arterial wall function using ultrasound technique. Clin Physiol 1997; 17: 557–67
   PubMedGoogle Scholar
• Fei G. Z., Svenungsson E., Frostegard J., Padyukov L. The A‐1087IL‐10 allele is associated with cardiovascular disease in SLE. Atherosclerosis 2004; 177: 409–14
   PubMed Web of Science ®Google Scholar
• Wright S. A., O'Prey F. M., Rea D. J., Plumb R. D., Gamble A. J., Leahey W. J., et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2006; 26: 2281–7
   PubMed Web of Science ®Google Scholar
• El‐Magadmi M., Bodill H., Ahmad Y., Durrington P. N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 27;110: 399–404
   Google Scholar
• Lima D. S., Sato E. I., Lima V. C., Miranda F Jr., Hatta F. H. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292–7
   PubMed Web of Science ®Google Scholar
• Rajagopalan S., Somers E. C., Brook R. D., Kehrer C., Pfenninger D., Lewis E., et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677–83
   PubMed Web of Science ®Google Scholar
• Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., et al. Reduced flow‐mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006; 27: 211–17
   PubMed Web of Science ®Google Scholar
• Piper M. K., Raza K., Nuttall S. L., Stevens R., Toescu V., Heaton S., et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16: 84–8
   PubMed Web of Science ®Google Scholar
• Bordron A., Revelen R., D'Arbonneau F., Dueymes M., Renaudineau Y., Jamin C., et al. Functional heterogeneity of anti‐endothelial cell antibodies. Clin Exp Immunol 2001; 124: 492–501
   PubMed Web of Science ®Google Scholar
• Blankenberg S., Rupprecht H. J., Bickel C., Peetz D., Hafner G., Tiret L., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336–42
   PubMed Web of Science ®Google Scholar
• Lewis M. J., D'Cruz D. Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus. Lupus 2005; 14((Suppl 1))s17–26
   Google Scholar
• Spronk P. E., Bootsma H., Huitema M. G., Limburg P. C., Kallenberg C. G. Levels of soluble VCAM‐1, soluble ICAM‐1, and soluble E‐selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long‐term prospective study. Clin Exp Immunol 1994; 97: 439–44
   PubMed Web of Science ®Google Scholar
• Ho C. Y., Wong C. K., Li E. K., Tam L. S., Lam C. W. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule‐1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42: 117–22
   PubMedGoogle Scholar
• Ikeda Y., Fujimoto T., Ameno M., Shiiki H., Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM‐1. Lupus 1998; 7: 347–54
   PubMedGoogle Scholar
• Madge L. A., Pober J. S. TNF signaling in vascular endothelial cells. Exp Mol Pathol 2001; 70: 317–25
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Gunnarsson I., Fei G. Z., Lundberg I. E., Klareskog L., Frostegard J. Elevated triglycerides and low levels of high‐density lipoprotein as markers of disease activity in association with up‐regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533–40
   PubMed Web of Science ®Google Scholar
• Boehme M. W., Raeth U., Galle P. R., Stremmel W., Scherbaum W. A. Serum thrombomodulin – a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 2000; 119: 189–95
   PubMed Web of Science ®Google Scholar
• Boehme M. W., Nawroth P. P., Kling E., Lin J., Amiral J., Riedesel J., et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 572–7
   PubMedGoogle Scholar
• Frijns R., Fijnheer R., Schiel A., Donders R., Sixma J., Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol 2001; 28: 514–19
   PubMedGoogle Scholar
• Frijns C. J., Derksen R. H., De Groot P. G., Algra A., Fijnheer R. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol 2001; 125: 149–54
   PubMedGoogle Scholar
• Chan S. H., Chen J. H., Li Y. H., Lin L. J., Tsai L. M. Increasing post‐event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol 2006; 111: 280–5
   PubMedGoogle Scholar
• Karmochkine M., Boffa M. C., Piette J. C., Cacoub P., Wechsler B., Godeau P., et al. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood 1992; 79: 837–8
   PubMedGoogle Scholar
• Jensen‐Urstad K., Svenungsson E., de Faire U., Silveira A., Witztum J. L., Hamsten A., et al. Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. Lupus 2002; 11: 744–52
   PubMed Web of Science ®Google Scholar
• Makris T. K., Stavroulakis G. A., Krespi P. G., Hatzizacharias A. N., Triposkiadis F. K., Tsoukala C. G., et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783–8
   PubMed Web of Science ®Google Scholar
• Pasini A. F., Garbin U., Nava M. C., Stranieri C., Pellegrini M., Boccioletti V., et al. Effect of sulfhydryl and non‐sulfhydryl angiotensin‐converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 443–50
   PubMed Web of Science ®Google Scholar
• Freestone B., Chong A. Y., Nuttall S., Blann A. D., Lip G. Y. Soluble E‐selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132: 1253–8
   PubMed Web of Science ®Google Scholar
• Hafstrom I., Rohani M., Deneberg S., Wornert M., Jogestrand T., Frostegard J. Effects of low‐dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis – a randomized study. J Rheumatol 2007; 34: 1810–16
   PubMed Web of Science ®Google Scholar